[go: up one dir, main page]

IS8501A - Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar - Google Patents

Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar

Info

Publication number
IS8501A
IS8501A IS8501A IS8501A IS8501A IS 8501 A IS8501 A IS 8501A IS 8501 A IS8501 A IS 8501A IS 8501 A IS8501 A IS 8501A IS 8501 A IS8501 A IS 8501A
Authority
IS
Iceland
Prior art keywords
cannabinonide
azate
receptor antagonists
cyclic heterocycles
heterocycles
Prior art date
Application number
IS8501A
Other languages
English (en)
Icelandic (is)
Inventor
William R Ewing
Yu Guixue
Bruce A Ellsworth
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IS8501A publication Critical patent/IS8501A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
IS8501A 2003-12-19 2006-06-08 Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar IS8501A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53145103P 2003-12-19 2003-12-19
PCT/US2004/042542 WO2005061509A1 (en) 2003-12-19 2004-12-20 Azabicyclic heterocycles as cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
IS8501A true IS8501A (is) 2006-06-08

Family

ID=34710226

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8501A IS8501A (is) 2003-12-19 2006-06-08 Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar

Country Status (11)

Country Link
US (1) US7037910B2 (xx)
EP (1) EP1699796A4 (xx)
JP (1) JP2007514756A (xx)
CN (2) CN1918165A (xx)
AR (2) AR047063A1 (xx)
IS (1) IS8501A (xx)
NO (1) NO20062689L (xx)
PE (2) PE20051047A1 (xx)
TW (2) TW200528455A (xx)
WO (1) WO2005061509A1 (xx)
ZA (2) ZA200604645B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
EP1430033A4 (en) 2001-08-31 2004-12-15 Univ Northwestern ANTI-INFLAMMATORY AND PROTEIN-INK-INHIBITING COMPOSITION AND THEIR USE
DK1697371T3 (da) 2003-12-19 2007-09-17 Bristol Myers Squibb Co Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
US20060025448A1 (en) * 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
MX2007005247A (es) 2004-11-02 2008-03-13 Univ Northwestern Compuestos de piridazina, composiciones y metodos.
ATE523199T1 (de) * 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
AU2007239033B2 (en) 2006-03-30 2011-12-15 Irm Llc Azolopyrimidines as inhibitors of Cannabinoid 1 activity
AU2007243280A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
US8158627B2 (en) * 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EA014915B1 (ru) * 2006-05-04 2011-02-28 Солвей Фармасьютикалс Б.В. Мускариновые агонисты для лечения расстройств контроля над побуждениями
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN110403942A (zh) * 2007-04-11 2019-11-05 奥默罗斯公司 预防和治疗成瘾的组合物和方法
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009137335A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute Synthesis of (+) corstistatin a and related compounds
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
FR2958850B1 (fr) * 2010-04-14 2012-07-06 Centre Nat Rech Scient Medicaments pour la prevention ou le traitement des addictions aux drogues
CN102985402B (zh) * 2010-04-20 2015-04-29 罗马大学 反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
CA2937967C (en) * 2014-01-29 2022-07-26 Neuropore Therapies, Inc. Heteroaryl amides as inhibitors of protein aggregation
WO2017210540A1 (en) * 2016-06-03 2017-12-07 The Trustees Of Columbia University In The City Of New York Methods of treating prader-willi syndrome
CN108178759B (zh) * 2018-01-05 2020-06-09 上海瑞纷医药科技有限责任公司 一种α-肾上腺素受体拮抗剂的合成方法
CN108498511A (zh) * 2018-04-21 2018-09-07 徐晶 一种治疗膝关节骨性关节炎的药物组合物及其制备方法
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164198B (it) * 1983-04-28 1987-04-08 Isf Spa Preparazione di un derivato piridazinico farmacologicamente attivo
US6610694B1 (en) * 1998-10-06 2003-08-26 Takeda Chemical Industries, Ltd. Condensed pyridazine compounds, their production and use
JP2002205992A (ja) * 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
EP1471917A1 (en) * 2002-02-07 2004-11-03 Pfizer Limited Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
JP2005526811A (ja) * 2002-03-25 2005-09-08 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療または予防用β−アミノ複素環式ジペプチジルペプチダーゼ阻害剤
WO2004074259A1 (en) 2003-02-19 2004-09-02 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds

Also Published As

Publication number Publication date
CN1918165A (zh) 2007-02-21
NO20062689L (no) 2006-09-12
WO2005061509A1 (en) 2005-07-07
EP1699796A1 (en) 2006-09-13
AR046964A1 (es) 2006-01-04
ZA200604778B (en) 2007-12-27
US20050192278A1 (en) 2005-09-01
CN1918164A (zh) 2007-02-21
EP1699796A4 (en) 2009-03-04
TW200528455A (en) 2005-09-01
TW200530246A (en) 2005-09-16
AR047063A1 (es) 2006-01-04
ZA200604645B (en) 2007-11-28
JP2007514756A (ja) 2007-06-07
PE20051047A1 (es) 2005-12-16
PE20050756A1 (es) 2005-10-06
US7037910B2 (en) 2006-05-02

Similar Documents

Publication Publication Date Title
IS8501A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
DE602004030930D1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
NO20051871D0 (no) Opioid reseptorantagonister
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
DK1951660T3 (da) Histamin-3-receptorantagonister
ATE413400T1 (de) Cgrp-rezeptorantagonisten
IS8119A (is) Þétt N-heteróhringlaga efnasambönd og notkun þeirra sem CRF viðtakamótlyfja
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
IL192309A0 (en) Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
IS8313A (is) Sýklískar afleiður sem stillar kemókínviðtakavirkni
ATE452886T1 (de) Chemokinrezeptorantagonisten
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
TWI348467B (en) Nk1 antagonists
DE602004004278D1 (de) 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
IL173512A0 (en) Cyclopropyl derivatives as nk3 receptor antagonists
DE60332816D1 (de) Nk1-antagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
IS8291A (is) Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar
IS8117A (is) 3-Flúr-píperidín sem NMDA/NR2B mótlyf
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
EP1819342A4 (en) QUINOLINE tachykinin ANTAGONISTS
IL179905A0 (en) Piperazinediones as oxytocin receptor antagonists
IS8091A (is) Hringtengd bensimídasól
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf